A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Pridopidine (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- Acronyms Open PRIDE-HD
- Sponsors Teva Branded Pharmaceutical Products R&D
- 05 Mar 2018 This trial has been discontinued in Italy.
- 26 Jan 2018 This trial has been discontinued in Netherlands.
- 12 Dec 2017 Planned End Date changed from 27 Apr 2023 to 31 Jan 2018.